Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma

Summary

A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled 28-week Phase 3 Efficacy and Safety Study of Tezepelumab in Reducing Oral Corticosteroid Use in Adults with Oral Corticosteroid Dependent Asthma

Timeline

Start

2022-08-09

Primary completion

2025-03-24

Completion

2025-03-24

Publications

• Wechsler ME, Brightling CE, Brusselle G, Caminati M, Soler T, Gonzalez EM, Nakwan N, Capala-Szczurko I, Hunter G, Almqvist G, Lal H, Kabelis P, Scrigner P, Matsunaga Y, Molfino N, Ponnarambil SS; SUNRISE study investigators. Efficacy and safety of tezepelumab versus placebo in reducing oral corticosteroid use in adults with severe, oral corticosteroid-dependent asthma (SUNRISE): a multicentre, placebo-controlled, double-blind, phase 3 trial. Lancet Respir Med. 2026 Jun;14(6):481-492. doi: 10.1016/S2213-2600(26)00076-7. Epub 2026 May 18.

Drugs

Indications